FTD.F FIN.DE TUBIZE ACT.NOUV.
- Market cap
- EUR 10.6B
- P/E
- 108.1x
- P/B
- 5.44x
- ROE
- 4.9%
- Dividend yield
- 0.44%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is FTD.F undervalued?
Graham numberThe Graham number of FIN.DE TUBIZE ACT.NOUV. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FIN.DE TUBIZE ACT.NOUV. fundamental analysis
No fundamental analysis for FIN.DE TUBIZE ACT.NOUV. yet.
FIN.DE TUBIZE ACT.NOUV. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About FIN.DE TUBIZE ACT.NOUV.
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
Full company profileFIN.DE TUBIZE ACT.NOUV. financial statements
FIN.DE TUBIZE ACT.NOUV. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.50M | -1.83M | -2.08M | -2.24M | -2.97M |
| Operating Income | -1.53M | -1.82M | -2.14M | -2.24M | -2.97M |
| EBITDA | - | 86.9M | 90.5M | 92.6M | 93.9M |
| Net Income | 83.6M | 85.2M | 88.2M | 90.1M | 93.2M |
| EPS | 1.88 | 1.91 | 1.98 | 2.02 | 2.09 |
| Balance Sheet | |||||
| Total Assets | 1.76B | 1.84B | 1.92B | 1.93B | 1.93B |
| Total Liabilities | 54.4M | 87.2M | 124M | 89.3M | 48.6M |
| Shareholders' Equity | 1.70B | 1.75B | 1.80B | 1.84B | 1.89B |
| Cash & Short-term Investments | 15.9M | 1.07M | 575K | 1.43M | 368K |
| Cash Flow | |||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.16M | -2.11M | -2.05M | -2.07M | -3.37M |
| Ratios | |||||
| ROE | 4.9% | 4.9% | 4.9% | 4.9% | 4.9% |
| ROA | 4.8% | 4.6% | 4.6% | 4.7% | 4.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
FIN.DE TUBIZE ACT.NOUV. dividends
- Dividend yield
- 0.44%
- Forward dividend
- 1.08 EUR
- Payout ratio
- 49.7%
- Ex-dividend date
- May 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 46.3M | 1.04 | 49.7% |
| 2024 | EUR 43.2M | 0.97 | 47.9% |
| 2023 | EUR 38.3M | 0.86 | 43.4% |
| 2022 | EUR 33.4M | 0.75 | 39.2% |
| 2021 | EUR 30.3M | 0.68 | 36.2% |
| 2002 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns FIN.DE TUBIZE ACT.NOUV.
- Insiders 53.49%
- Institutions 8.89%
- Public & others 37.62%
- Shares outstanding 44.5M
- Free float 20.7M
FIN.DE TUBIZE ACT.NOUV. company profile
- Company name
- FIN.DE TUBIZE ACT.NOUV.
- Ticker
- FTD.F
- ISIN
- BE0003823409
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Allée de la Recherche 60, Brussels, Belgium, 1070
- Phone
- 32 4 9751 5208
- Website
- financiere-tubize.be
About FIN.DE TUBIZE ACT.NOUV.
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
FIN.DE TUBIZE ACT.NOUV. management
2- Mr. Eric NysManaging Director
- Ms. Anne Sophie PijckeGeneral Manager